NASDAQ · ABP
Abpro Holdings, Inc.
$0.52 -$0.28 (-34.76%) 1DKey Metrics
$12.49M
Market cap
4.37×
P/E · TTM
—
Revenue · TTM
$2.86M
Net income
EPS · TTM
$1.68
Dividend yield
—
Free cash flow
—
Beta · 1Y
2.53
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap$12.49M
Enterprise value—
Shares outstanding2.7M
52-wk range$0.52 – $10.87
Avg volume · 20D493.0K
Net cash
—
Book value / share$-1.65
IndustryBiological Products, (No Disgnostic Substances)
ExchangeNASDAQ
About Abpro Holdings, Inc.
IPO dateNov 13, 2024
Employees6
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E4.37
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
-31.3% · —
Financial Health
Current ratio0.74
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital−$2.42M
Cash Flow · TTM
Operating CF
—
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
0 / 9
Weak fundamentals · 0 of 9 signals passing
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings